WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2025 financial results on November 4, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investo ...

WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2025 financial results on August 11, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines ...

Core Insights - Kymera Therapeutics, Inc. is set to host a video webcast on May 9, 2025, to report its first quarter 2025 financial results and introduce a new oral development candidate targeting autoimmune and rheumatic diseases [1] - The company will also review highlights and upcoming milestones in its immunology pipeline, which is considered industry-leading [1] Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation (TPD) to develop innovative medicines for significant health issues [3] - The company aims to create a pipeline of oral small molecule degraders that offer convenient and effective therapies for patients with immunological diseases [3] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [3] Communication and Information Availability - Investors and the public can access information about Kymera through its website, including corporate disclosures, investor presentations, and SEC filings [4] - The company encourages regular review of the information posted on its website and social media platforms [4]